One Sentence Summary: Microengineered Organ-Chip technology has been used to design rat, dog and human Liver-Chips that recapitulate species-specific liver toxicities.
animals (2) . The poor prediction of liver toxicity in humans is driven by poor nonclinical to clinical translation and by rare idiosyncratic events that occur in large patient trials or at postmarketing. Thus, one of the major challenges the pharmaceutical and biotechnology industries face is selecting compounds with reduced risk for hepatotoxicity-the major cause for liver failure and drug attrition (3) (4) (5) (6) . Given the scale of this challenge and its negative impact on healthcare costs and development of new therapeutics, there is a critical need for more predictive and human relevant alternatives to animal models. Here, we explored whether human microengineered Organ-on-Chip (Organ-Chip) technology, which has been shown to faithfully recapitulate the complex functions and pathophysiology of multiple human organs (7) (8) (9) (10) (11) , may be used to design species-specific Liver-Chips that can be used to address this challenge.
Development and Characterization of rat, dog, and human Liver-Chips
Species-specific Liver-Chips lined by living rat, dog, or human hepatic cells were constructed using Organ-Chips that have previously been shown to recapitulate the multicellular architecture, tissue-tissue interface, vascular perfusion, fluid flow, and relevant physical microenvironment of multiple human organs, including lung, intestine, and kidney (10) (11) (12) .
Primary rat, dog, or human hepatocytes were seeded in the upper parenchymal channel within an extracellular matrix (ECM) sandwich (13) on top of an ECM-coated, porous membrane that separates the two parallel microchannels. Relevant species-specific rat, dog, or human liver sinusoidal endothelial cells (LSECs), with or without liver Kupffer cells and/or stellate cells, were cultured on the opposite side of the same membrane in the lower vascular channel (Fig.   1A) . We initiated these studies by analyzing dual-cell Liver-Chips containing only the hepatocytes and LSECs ( fig. S1A) , which revealed that all three species of primary hepatocytes formed characteristic branched bile canalicular networks lined by functional multidrug resistance-associated protein 2 (MRP2) efflux transporters and maintained their stereotypical in vivo-like liver epithelial morphologies and cytoarchitecture for at least 14 days in culture under continuous flow ( fig. S1B) . In contrast, the same human, dog, and rat hepatocytes failed to form well developed bile canaliculi when maintained for 14 days without endothelium in the conventional static ECM sandwich culture plates ( fig. S1B) . It has been reported that sandwich culture can also form extensive canalicular network, but these are not sustained over 14 days and generally only over 7 days in culture (14, 15) . In the microengineered Liver-Chip, the underlying vascular channel containing LSECs also displayed the multifunctional scavenger receptor stabilin-1, which is expressed selectively on sinusoidal endothelial cells of liver, spleen, and lymph nodes (fig. S1B) (16) .
To assess the liver-specific physiological function of the dual-cell Liver-Chips, we measured secretion of albumin and compared this to results obtained from the same human, rat, and dog hepatocytes cultured alone in the static sandwich culture plates. These studies revealed that all three species-specific Liver-Chips maintained significantly higher (3-to 14-fold greater) levels of albumin production than cells in conventional sandwich monoculture plates ( fig. S1C) .
Importantly, the quantitative range of albumin production we measured in the human Liver-Chip of ~20-70 µg/day/million cells (between days 7 and 14) was very similar to that estimated for humans in vivo (50 µg/day/million cells) using in vitro-to-in vivo extrapolation (iViVE) techniques (17) . In contrast, hepatocytes within conventional sandwich monoculture plates showed significantly lower (2.8-to 3.9-fold lower) levels of albumin production than cells in the human Liver-Chip over the same time period.
To further evaluate the physiological relevance of the dual-cell Liver-Chips, the drug metabolizing capacity of the hepatocytes were characterized over time in culture. We measured the activities of the 3 major cytochrome P450 (CYP) isoforms (CYP1A, CYP2B, and CYP3A) that represent key CYP families involved in drug metabolism. We used prototypical probe substrates in a cocktail approach using concentrations of their respective substrates (phenacetin, bupropion, and midazolam) or a single substrate (cyclophosphamide for CYP2B and testosterone for CYP3A for human model) that mirror their Michaelis constant (Km) in humans (18) . These three isoforms also represent the major CYPs regulated by the xenosensors: aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), and pregnane X receptor (PXR) (19) .
Importantly, these studies revealed that CYP activities measured in the dual-cell human, rat, and dog Liver-Chips over the 14-day culture period were comparable to, or in some cases greater than, those exhibited by freshly isolated hepatocytes ( fig. S2) , which are the gold-standard model currently used by pharmaceutical researchers. In contrast, there was a significant decline in CYP activities in all three species in sandwich monoculture plates over the same time period (fig. S2) .
Recapitulation of species-specific drug toxicities in rat, dog, and human Liver-Chips
To explore whether these dual-cell Liver-Chips could be used to predict species-specific drug induced liver injury (DILI) responses, we used the three species models to evaluate hepatotoxic effects induced by bosentan, a dual endothelin receptor antagonist that causes cholestasis in humans, but not in rats or dogs, by inhibiting the bile salt export pump (BSEP) and inducing hepatocellular accumulation of bile salts (20, 21) . Daily administration of bosentan at 1, 3, 10, 30, or 100 μM resulted in decreases in albumin secretion with different potencies in these species-specific Liver-Chips, with an IC50 of 10, 30 and >100 μM in human, dog, and rat chips, respectively (Fig. 1B) . We observed a correlation between the effect in the human Liver-Chip with the clinical response. Notably the concentration in the human Liver-Chip at which we observed toxicity approximated to the plasma concentrations of bosentan (Cmax = 7.4 μM) that have been associated with DILI in humans (22) . In addition, the model was more sensitive in detecting bosentan toxicity compared to sandwich monoculture plates (Fig. 1B ) which failed to demonstrate an in vivo relevant toxic response. In other complex cell-based liver models including 3D human spheroid hepatic cultures the IC50 was found to be more than 10-fold higher than in vivo (23) . Co-treatment of bosentan (30 μM) with cholyl-lysyl-fluorescein (CLF), a BSEP substrate, inhibited efflux of CLF by 50% (Fig. 1C) resulting in its intracellular accumulation (Fig. 1D) in the Liver-chip consistent with the known mechanism for hepatotoxicity of bosentan in humans. Inhibition of BSEP activity was also accompanied by decreases in BSEP protein and mRNA levels (Fig. 1E) . Thus, in addition to recapitulating species-specific hepatotoxicities, these results illustrate that mechanisms of DILI which involve hepatic transporters can be studied in the Liver-Chip. This highlights the advantage of the LiverChip in integrating mechanisms of action (in this case BSEP transporter inhibition) to functional outcome (decrease in albumin synthesis) in the same model.
Detection of diverse phenotypes of hepatotoxicity using quadruple-cell Liver-Chips
To add a higher order of biological complexity to the Liver-Chip necessary to study diverse phenotypes of liver toxicity, we integrated species-specific, non-parenchymal cells (NPC), hepatic stellate and Kupffer cells into the vascular channel to develop the quadruple-cell Liver-Chip model (Fig. 1A) . These species-specific, quadruple-cell Liver-Chips also exhibited high levels of albumin secretion similar to those observed in the dual-cell Liver-Chips ( fig. S3A) .
The human and rat quadruple-cell Liver-Chips also maintained high levels of CYP enzyme activities that were similar to, or higher than, those observed in freshly isolated hepatocytes or in the dual-cell Chips ( fig. S3B ) over long-term culture. We used tool compounds that are known to cause diverse phenotypes of DILI or transaminitis in humans to characterize the ability to use the Liver-Chip for safety and risk assessment in humans and to enable insights into mechanism of action driving the toxicity.
The generic analgesic acetaminophen (APAP) can produce DILI resulting in whole organ failure and death when over-dosed. APAP toxicity is caused by direct injury to hepatocytes mediated by the toxic and reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) that depletes cellular glutathione (GSH) causing oxidative stress; it can also be detoxified by hepatocytes resulting in formation of glucuronide and sulfate metabolites (24) . To evaluate APAP toxicity in the human quadruple-cell Liver-Chip, we maintained a constant flow rate that was determined to best reproduce its metabolism rate and turnover (10 μL/hr of flow rate) based on its known intrinsic clearance. Metabolism of APAP on the Liver-Chip was confirmed by detection of significant amounts of APAP glucuronide in both the parenchymal and vascular channels following daily administration of 3 mM APAP for 20 days ( fig. S4A) , which confirmed that all four cell types were exposed to the hepatocyte-derived metabolites as a result of diffusion through the porous membrane. Importantly, treatment with APAP resulted in dose-dependent depletion of total GSH and ATP at all concentrations tested (0.5, 3, and 10 mM) in the hepatocytes within the parenchymal channel, and even more potently in the NPCs in the vascular channel ( Fig. 2A) , highlighting that APAP toxicity is not limited to liver epithelial cells. The depletion of GSH also is suggestive of formation of reactive oxygen species (ROS), which we confirmed by measuring their levels using a fluorescent reporter assay (Fig. 2B) . APAP-induced depletion of GSH and ATP was followed by a decline in hepatocyte morphology ( fig. S4B ) and function, as measured by decreased albumin synthesis and oxidative stress-related injury markers such as alpha glutathione S-transferase (α-GST) and microRNA 122 (miR122) (Fig. 2C) . In addition, co-treatment of APAP (3 mM) with the glutathione depleting agent buthionine sulfoximine (BSO; 200 μM) amplified sensitivity to APAP toxicity. This was seen by the increased release of ROS (Fig. 2B) , miR122, and α-GST (Fig. 2C ) that were not detected at the same APAP concentration in the absence of BSO. Taken together this confirms the reported role of ROS in APAP-induced hepatotoxicity (25) .
To explore whether the quadruple-cell Liver-Chips could be used to model DILI mechanisms that target Kupffer cells, we studied JNJ-1, a colony stimulating factor-1 (CSF-1) receptor kinase inhibitor. This compound caused minimal elevations in transaminases (<3-fold) in a human Phase I clinical trial that was attributed to Kupffer cell depletion which can play a role in the clearance of transaminases (26) . Very high transaminase levels were reported in two individuals (>10-fold) and were considered idiopathic and unique to the compound (Janssen unpublished data). Minimal dose-related elevations in transaminases (<3-fold) were also observed in rat and dog studies (Janssen unpublished data), but without any correlative microscopic changes in the liver. Kupffer cell depletion observed in the clinic and detected by decreased number of CD68-positive cells was reproduced in human Liver-Chip following administration of JNJ-1 at 3 μM (Fig. 3A) , a dose relevant to clinical human concentrations (Cmax ~2 μM). Kupffer cell depletion was associated further with a decrease in interleukin 6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) (Fig. 3B) in the vascular channel but was without an effect on hepatocyte function. Importantly, decreased hepatocyte function as measured by lowering of albumin secretion was only observed at 30 μM of JNJ-1, about 15-fold above the human Cmax (Fig. 3C) , suggesting potential for intrinsic toxicity only at high concentrations. These results demonstrated the ability of the human quadruple-cell Liver-Chip to detect a clinically-relevant mechanism of action that targets Kupffer cells, independently of hepatocytes.
Modeling steatosis and markers of fibrosis on-Chip
Methotrexate (MTX) causes liver injury in humans characterized by steatosis, stellate cell hypertrophy, and fibrosis at maximal plasma concentrations of ~1 μM in some patient populations (27) . Importantly, these findings were recapitulated in the human quadruple-cell Liver-Chip where daily administration of MTX at 1, 10, or 30 μM for 7 days resulted in microscopic evidence of lipid accumulation as detected by Nile red staining, and stellate cell activation as indicated by increased expression of α-smooth muscle actin (α-SMA) (Fig. 3D, E) .
These changes were also associated with increases in interferon γ-induced protein 10 kDa (IP-10), a chemokine whose elevation is associated with liver inflammation and fibrosis (28) . There were no abnormalities in albumin secretion (Fig. 3F ) or hepatocyte morphology (not shown), which is consistent with the lack of predictive or diagnostic biomarkers for monitoring these toxicities in humans. These studies suggest that inclusion of microscopic endpoints for steatosis and markers of fibrosis in the quadruple-cell Liver-Chip could be an approach to identify compounds with a potential risk for these toxicities.
To investigate whether cross-species Liver-Chip models could be used to predict humanspecific steatosis, fialuridine (FIAU) was tested in rat and human quadruple-cell Liver-Chips.
Development of FIAU, an anti-viral nucleoside analog, was discontinued in Phase II clinical trials due to liver failure and deaths in 5 out of 15 patients, caused by microvesicular steatosis (29) . A review of the animal toxicology data concluded that the studies could not have predicted severe liver injury in humans caused by FIAU (27) . Daily administration of FIAU at 1, 10, or 30 µM for 10 days in the human Liver-Chip resulted in a dose-dependent increase in lipid accumulation (Fig. 4A) . There was also a concomitant dose-dependent decline in albumin secretion at concentrations ≥ 1 μM, and release of liver injury markers including miR122, α-GST, and keratin 18 (K-18) (Fig. 4B, C) . In contrast, there were no effects on lipid accumulation or hepatocyte function following treatment in the rat Liver-Chip with FIAU at the same concentrations and treatment duration as the human Liver-Chip (Fig. 4A, B) , which is consistent with past nonclinical studies and species differences observed in vivo (29) .
Use of species-specific Liver-Chips to query human relevance of animal liver toxicities It is not uncommon for compounds to be discontinued due to liver toxicity observed in rats or dogs prior to testing in humans because of uncertainties on the human relevance of these findings. To evaluate whether species-specific Liver-Chips could be used to assess human relevance, a Janssen proprietary compound that was discontinued due to liver toxicity in rats was characterized in the cross-species Liver-Chips. Daily oral administration of JNJ-2 to rats for 2 weeks resulted in liver fibrosis, supported by increased α-SMA staining within stellate cells, at 150 mg/kg (Cmax = 11.6 μg/mL; 24 μM) that was persistent 3 months after compound wash-out (Fig. 5A) . These findings were associated with chronic inflammation of portal areas and decreases in albumin with no changes in transaminases in rats, and as a result, JNJ-2 was discontinued prior to testing in non-rodent species. Interestingly, daily treatment of JNJ-2 at 3, 10, or 30 µM in rat quadruple-cell Liver-Chip for 4 days resulted in a dose-dependent increase in expression of α-SMA, a marker for fibrosis, within stellate cells (Fig. 5B, C) ; decreases in albumin were observed, but did not reach significance (Fig. 5D) . In contrast, treatment of human Liver-Chips at the same concentrations did not produce these abnormalities, even when extended for 14 days of treatment (Fig. 5B, C, D) . These results imply a potential species differences in response between rats and humans with JNJ-2.
We also tested another Janssen proprietary compound, JNJ-3, that was discontinued from further development due to hepatocellular necrosis, portal fibrosis, and biliary hyperplasia following daily dosing at 15 and 65 mg/kg for 14 days in dogs at maximal plasma concentrations of 12.7 and 19.4 μM, respectively (Fig. 5E ). These findings were associated with significant elevations of ALT and AST after 6 or 14 days of treatment (Fig. 5F ). JNJ-3 was administered to dog and human Liver chips for 4 days after which the study was stopped due to significant damage to hepatocytes at the highest concentrations tested, and biochemical endpoints were measured in samples collected at 24 hours post-dose. Administration of JNJ-3 significantly decreased albumin secretion at ≥ 1 μM in dog Liver-Chips, and at ≥10 μM in human Liver-Chips (Fig. 5G) . ALT, AST, and glutamate dehydrogenase (GLDH) were also elevated in dog and human Liver-Chips, but only at the highest concentrations of 10 and 30 μM, respectively ( 
Identifying risk for idiosyncratic DILI using the Human Liver-Chip
One of the most difficult forms of hepatotoxicity to predict in the clinic relates to idiosyncratic DILI responses that are often missed during nonclinical and early clinical testing.
To explore whether the human Liver-Chip might be useful to predict these types of response, we tested TAK-875, a GPR40 agonist that was discontinued in Phase III trials due to low incidence inhibition by TAK-875AG formed in the human Liver-Chip (Fig. 6B) . This allowed us to probe the consequences of prolonged exposures to TAK-875 and its formed reactive metabolite TAK-875AG in Liver-Chip in a 2-week study. We found an effect on mitochondrial membrane potential, confirmed by a dose-related and time-dependent redistribution of the mitochondrial potential sensitive dye tetramethylrhodamine methyl ester (TMRM) detected at 1 week of treatment (Fig. 6B,C) , and lipid droplet accumulation and formation of ROS (Fig. 6B,C) at the end of the 2-week treatment; these endpoints may be consequential to perturbation of the mitochondria. We then investigated whether an innate response could be detected in Liver-Chip treated with TAK-875 based on the prevailing hypothesis for immune-mediated DILI that an innate response caused by covalent protein binding, cell stress, and release of damage associated molecular patterns (DAMPs) can trigger an adaptive immune attack of hepatocytes in a few susceptible individuals (33) . Treatment with TAK-875 caused a biphasic and significant release of the inflammatory cytokines MCP-1 and IL-6 at 10 µM (human equivalent Cmax) but not at 30 µM (Fig. 6D) ; lack of cytokine release at higher concentrations could be due to reduced cell health resulting from ROS formation.
Discussion
These results suggest that species-specific Liver-Chips can be used to predict rat, dog, and human hepatotoxicities, and that they may be used to estimate human relevance of liver toxicities seen in animals for safety and risk assessment. They also could potentially be used to predict human idiosyncratic hepatotoxicities and elucidate mechanisms of action.
Ongoing research on DILI ranges from basic understanding of adverse pathways and mechanisms by which some compounds cause DILI to clinical research aimed at identifying predictive DILI biomarkers. This research is spurred by human safety concerns for liver failure and the associated high costs incurred when these drugs are withdrawn from clinical trials or from the market based on incorrect predictions from nonclinical testing. Recently, the FDA released a Predictive Toxicology Roadmap aimed at qualifying in silico and in vitro models to enable their use in regulatory decision making; qualification of these models will encourage their uptake and use, which would also meet objectives of reduction, refinement, and replacement of animals. While there are significant advances in the development of in vitro models that predict DILI, key gaps remain that need to be addressed. For example, lack of metabolic competence in plated primary hepatocytes has been addressed by more complex 2D co-culture or 3D spheroid models, which can maintain metabolic competence for prolonged durations (14, (34) (35) (36) . But these models are static and closed, therefore, metabolites may accumulate to levels that are not physiologically relevant or they may be underrepresented due to loss following medium replenishment that is required to maintain cell survival. In addition, dense 3D constructs often suffer from limited oxygen and nutrient transport, and even when spheroid cultures include endothelial cells and Kupffer cells, they lack physiologically relevant tissue-tissue interfaces and cytoarchitecture that has been demonstrated to be a key driver of cell function (10, 37) . It is also impossible to apply physiologically relevant fluid flow and associated mechanical forces in which drugs pass specifically through an endothelium-lined interface as they do in vivo.
Mechanical forces have also been demonstrated to be a key player in gene expression and in vivo cell function (10) . In addition, in spheroids it is difficult to visualize dynamic changes in cell position, morphology, or function within these large, disorganized, and multi-cellular structures.
Recently, there has been many attempts to develop liver-based cell systems to replicate organ-level functions using microengineered approaches, such as microphysiological systems (MPS), and some have included the four cell types we included in the quadruple-cell Liver-Chips in the present study (38) (39) (40) . Some of these studies demonstrated enhanced functionalities with flow (e.g., increased albumin secretion and CYP activities) but were limited to short-term (e.g., 1 day) cultures (38) . In contrast, in the present study, we showed that both the dual-cell and quadruple-cell Liver-Chips remain metabolically competent and maintain albumin production as well as activities of multiple key drug metabolizing enzymes at in vivo-like levels for at least 14 days in culture. More importantly, while DILI responses to various drugs were measured in other MPS liver models (36, 39, 41) , the drug concentrations utilized were not clinically relevant. In contrast, we used drug levels similar to those observed in the plasma of animals and patients in the present study, and as a result, we were able to generate results that closely recapitulate those previously reported in both nonclinical animal studies and human clinical trials.
Endpoints assessed in most in vitro systems are limited to measures of cell viability as an initial assessment of potential hazards, but they often do not capture the mechanisms that underlie DILI or clinical relevant endpoints, and they are not effective for human risk assessment. We evaluated whether the Liver-Chip could detect more complex and mechanistically relevant DILI endpoints. Using a combination of microscopy, tissue staining, and measurement of DILI biomarkers, we were able to detect diverse phenotypes of DILI including hepatocellular injury, cholestasis, steatosis, Kupffer cell depletion, and stellate activation as a marker of fibrosis. Thus, the quadruple-cell Liver-Chip appears to be suitable for detecting toxicities that are attributable to direct effects on the four liver cell types included in our model; however, they are currently not capable of detecting toxicities of the bile duct as this cell type has not yet been included in the design of the current Liver-Chip. It was interesting to note that, with the tool compounds tested so far, toxicities in the model were detected at concentrations that bridged human plasma levels associated with DILI, suggesting that the model has potential to be used for human risk assessment.
Although the enzymatic activities in human Liver-Chip were robust, some activities were lower or higher in comparison to fresh human hepatocytes, which most likely reflects donor to donor variability. The CYP enzyme activities in rat Liver-Chip were similar to those measured in fresh rat hepatocytes, when a single substrate was used, but they were higher when a cocktail of CYP substrates were used, which suggests potential for interactions among these substrates in the cocktail approach ( fig. S2, S3B) .
One advantage of the microengineered Liver-Chips is the use of continuous flow in an open system, which ensures that all cells are exposed sufficient levels of the parent drug and its metabolites simply by adjusting the flow rate. The open system also allows for continuous collection or sampling of the effluents of both the vascular and parenchymal channels, which prevents accumulation of the parent and its metabolites, while enabling measurement of biomarkers and other biology endpoints over time.
The ability to measure mechanistic endpoints and biomarkers in the model also makes it suitable for delineating pathways and mechanisms causing DILI. For instance, the observation that GSH and ATP depletion are early events in APAP-mediated toxicity followed by a decline in hepatocyte function and finally by oxidative stress and overt injury, suggests that toxic metabolite-mediated mitochondrial dysfunction and ATP depletion are likely early events in the APAP toxicity cascade. Indeed, mitochondrial dysfunction has been identified as a hazard for APAP toxicity (42) . Depletion of GSH and ATP in non-parenchymal cells following treatment with APAP implies that the toxic metabolite can escape hepatocytes and mediate an effect on other cell types. This is supported by studies in mice where APAP metabolites were detected bound to reticulocytes, which lack drug metabolizing enzymes, indicating that these metabolites also escape hepatocytes in vivo (43) . The increased sensitivity of NPCs to APAP toxicity compared to hepatocytes may be due to a reduced detoxification capacity relative to that in hepatocytes. The current studies in Liver-Chip confirm that both hepatocytes and nonparenchymal cells contribute to APAP hepatoxicity in vivo.
Specific contexts of use must be defined for predictive in vitro models, such as the LiverChip, prior to their qualification to make key decisions in the drug development process. These contexts of use can be developed in areas such as prediction of human liver toxicity, human relevance of toxicity observed in animal studies, or identifying DILI potential of compounds that form reactive metabolites. Results of our studies with bosentan, fialuridine, methotrexate, and JNJ-1 show that the human Liver-Chip can be used to study diverse mechanisms of responses in the liver with compounds that target parenchymal and non-parenchymal cells, and more importantly, that these occur at clinically relevant concentrations that bridge plasma concentrations where the effects were observed in humans. Human-specific sensitivities to toxicity by bosentan and FIAU were also confirmed in the human Liver-Chip compared to the companion animal Liver-Chips demonstrating specie-specific in vivo-in vitro correlation. The putative mechanism for bosentan -inhibition of bile acid efflux via BSEP resulting in intracellular accumulation of bile acids -was also confirmed; an advantage of the Liver-Chip is that we could couple these mechanistic endpoints to a measurable decline in hepatocyte function.
The species differences in bosentan toxicity may be related to species differences in the composition of toxic bile acids (21) . The species differences for FIAU is explained by species differences in expression and activity of the nucleoside transporter 1 (EMT1), which is absent in rats, but present in humans where it facilitates entry of FIAU into the mitochondrial membrane A gap exists in assigning human relevance of liver toxicities observed in animal studies, especially when these are observed in only one species. JNJ-2 and JNJ-3 are examples of compounds that caused liver toxicity in animal studies and were discontinued prior to clinical development; JNJ-2 caused fibrosis in rats, a finding that is not monitorable in humans, while JNJ-3 caused severe hepatocellular injury and biliary hyperplasia in dogs as early as a week after daily treatment. The rat Liver-Chip was very sensitive to treatment with JNJ-2, while no toxicity was observed in the human Liver-Chip at the same concentrations up to 14 days of daily treatment. Activation of stellate cells noted in rat, but not in human Liver-Chip, confirmed that we could reproduce the pathophysiology observed in rats in the rat Liver-Chip. Moreover, lack of a similar response in the human Liver-Chip suggests potential for species difference in the response. Although these results are interesting and could have influenced an internal decision to test the compound in non-rodents to address whether fibrosis was rat-specific, the model would need robust qualification with a specific context of use to convince regulatory agencies to make a decision with regards to the lack of human relevance of the rat findings. As we observed release of cytokines/chemokines including IP-10 in Liver-Chips treated with MTX, FIAU, and JNJ-2 which has been identified as a potential marker for fibrosis (46) , this model also may be amenable biomarker discovery, especially for more challenging disease areas, such as steatosis and fibrosis, where suitable biomarkers for monitoring in humans are lacking.
Reactive metabolite formation has been identified as an important hazard associated with compounds that cause rare or idiosyncratic DILI. The microengineered Liver-Chip provides an opportunity to put formation of reactive metabolites in a cell, tissue, and organ context for a functional readout of their contribution to DILI. For instance, putative adverse pathways for TAK-875-mediated DILI were detected in discrete in vitro models (30) , however, the physiological consequence of perturbing these mechanisms could not be studied. Treatment of Liver-Chip with TAK-875 showed that continuous and prolonged exposure to parent and reactive metabolites caused mitochondrial dysfunction, oxidative stress, formation of lipid droplets, and an innate immune response (i.e., cytokine release), all of which are harbingers of DILI for patients with increased susceptibility. Interestingly, in a 24-week Phase III clinical trial with TAK-875, liver biopsies of 5 of 7 patients that had abnormal transaminase levels in the study also presented with steatosis (47). However, it was challenging to assign causality because of disease background in Type 2 diabetic patients, but a treatment related effect could not be ruled out. The Liver-Chip studies suggest that steatohepatitis secondary to mitochondrial dysfunction and ROS formation could be a potential phenotype of DILI following treatment with TAK-875. This exemplifies the advantage of the Liver-Chip for assessing the pathophysiological consequence of reactive metabolite formation, which has been strongly associated with idiosyncratic DILI (33, 48, 49) .
In conclusion, we have shown that species-specific Liver-Chips have potential future application for safety testing, disease modeling, mechanism of action determination, biomarker identification, and predicting human hepatotoxicities, including idiosyncratic responses. This approach also could be used to query human relevance of toxicities observed in nonclinical animal studies or for mechanistic investigations of DILI detected in nonclinical and clinical studies.
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Liver-Chip culture
Prior to cell seeding, chips (S-1 Chips, Emulate, Inc. Boston, MA, USA) were functionalized using Emulate's proprietary protocols and reagents (ER™). After surface functionalization, both channels of the Liver-Chip were coated with species-specific extracellular matrices (ECM). For the human Liver-Chip, we used a mixture of collagen type I (Corning, Corning, NY, USA) and fibronectin (Gibco); for the rat Liver-Chip we used a mixture of and CellROX® (Thermo Fisher) to visualize cellular oxidative stress. Each staining solution was prepared in blank medium or compound dosing medium and added to the upper channel, incubated for 15 minutes at 37 °C, and washed three times with medium. The stained chips were imaged using a specific filter, and were de-blurred with Olympus cellSens software. Using ImageJ-Fiji, the fluorescent images were histogram adjusted to remove background, followed by fluorescence quantification using the Integrated Density calculation function.
Biochemical assays
Albumin secretion from the upper channel was quantified using ELISA kits for human, rat, and dog models effluent samples (human and rat: Abcam; dog: Immunology Consultants Laboratory, Inc., Portland, OR, USA) and the assays were performed according to the protocol provided by each vendor.
ATP and GSH
ATP was measured using a modified CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI, USA). Briefly 50 μL of cell lysate was mixed with 50 μL of ATP luminescent reaction mixture, incubate for 5 min, and luminescent intensity measured using a luminescence plate reader according to manufacturer's instruction. ATP concentrations in the lysates was quantified with an ATP standard curve. Mixed briefly on a plate shaker, incubated samples for 15 minutes and measured luminescence.
Raw luminescent numbers were quantified to total glutathione (μM) by using a total glutathione standard curve.
DILI Biomarkers
Keratin 18 (K18): levels were quantified in human model effluent samples from both the hepatocyte and vascular channels using the M65 EpiDeath CK18 ELISA Kit (DiaPharma, Detroit, MI, USA). The assay was run following the vendor protocol using a standard curve ranging from 0-5,000 U/L. Additionally, a standard curve ranging from 0-500 U/L was generated independently for quality control.
Alpha Glutathione S-Transferase (α-GST): levels were quantified in human model effluent samples from the upper channel using an ELISA kit (DiaPharma). The assay was run following the vendor protocol using a standard curve ranging from 0-64 µg/L. Additionally, a standard curve ranging from 0-50 µg/L was generated independently for quality control.
Mir-122: Isolation of micro-RNAs was performed on upper and lower chamber eluates using Qiagen's (Hilden, Germany) miRNA isolation kit for serum and plasma. A total volume of 50 L was used for isolation. Isolation was performed according to manufacturer's protocol using a 56.5 pM oligonucleotide spike-in control. Samples were eluted with 14 L RNase-free water.
Reverse transcription was performed using Thermo Fisher Scientific's TaqMan TM MicroRNA
Reverse Transcription Kit according to the manufacturer's protocol. A total reaction volume of 15 L was used. Real-time PCR was performed using Thermo Fisher Scientific's TaqMan®
Micro-RNA Assays according to manufacturer's protocol. A total reaction volume of 10 L was used. Normalized Ct was used for fold-change analysis.
Cytokines: Release of IL-6, MCP-1, and IP-10 from the vascular channel was quantified using U-PLEX biomarker human assays (Meso Scale Diagnostics, Rockville, MD, USA) and the assays were performed according to the protocol provided by the vendor.
Gene expression analysis
Gene expression levels were analyzed using 2-step PCR. Total RNA isolation was 
APAP metabolite quantification
After APAP exposure to human Liver-Chips, effluent metabolite levels were quantified using LC-MS analysis. area from LC-MS, and D is the dilution factor. APAP-Glucuronide (APAP-Glu), the primary metabolite of APAP, was not quantified using a standard curve. Rather, the LC-MS peak area of APAP-Glu was reported corresponding to each sample.
Testing of JNJ-2 in rats
Following the discovery of liver fibrosis in a 14-day male rat study with JNJ-2, a mechanistic study was performed with the same compound at the high dose, three time points (3, 7 , and 14 days), 12 male rats per group (6 euthanized at the end of treatment, and 6 after a 14-day recovery period). Regarding histology procedures, the liver was sampled. Briefly, 5 serial sections were prepared. One was stained with hematoxylin and eosin (H&E) kit. α-SMA intensity quantification: the fluorescent channel (588) was first background subtracted and processed using the median filter of Image J. After processing, the signal was thresholded using adaptive thresholding function of Image J (Otsu method) to extract fluorescent regions and to measure the relative intensity of the fluorescent signal. N=4 to 6 FOVs per chip from each chip were analyzed. All results were normalized to the relative control condition (vehicle, DMSO 0.1%) and reported as fold increment in respect to control.
Statistical analysis
As indicated in the figure legends, one-way ANOVA, Sidak's and Dunnett's multiple comparisons tests were used for parametric data and the Mann-Whitney U test or Kruskal-Wallis tests was used for nonparametric data. All statistical analyses were performed using Prism 7 (GraphPad). Cytochrome P450 enzyme activity in human, dog, and rat Liver-Chips compared to conventional sandwich monoculture plates and fresh hepatocyte suspension over 2 weeks using a cocktail (for dog and rat) or single (for human) probe substrate. Unit: pmol/min/10 6 cells. Sidak's multiple comparisons test (n=3~17 independent chips). *P < 0.05, **P < 0.01, ***P < 0.001 , ****P < 0.0001. Error bars present mean±SEM. 
